Publication: The current status of drug resistance in malaria
Issued Date
1987-01-01
Resource Type
ISSN
00207519
Other identifier(s)
2-s2.0-0023105555
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
International Journal for Parasitology. Vol.17, No.1 (1987), 169-180
Suggested Citation
Danai Bunnag, Tranakchit Harinasuta The current status of drug resistance in malaria. International Journal for Parasitology. Vol.17, No.1 (1987), 169-180. doi:10.1016/0020-7519(87)90038-5 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/15359
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
The current status of drug resistance in malaria
Author(s)
Other Contributor(s)
Abstract
Drug resistant malaria is a major health problem; it poses a threat to the lives of millions of people and renders it less possible for the worldwide eradication programme to attain its goal in the foreseeable future. At present Plasmodium falciparum is resistant to varying degrees to all antimalarial drugs available e.g. chloroquine, sulfadoxine and pyrimethamine, quinine and even to the new compound, mefloquine. Chloroquine-resistant P. falciparum originated in Thailand some 25 years ago has spread in all directions to Southeast Asia, Western Pacific, to central and southeast India, East Africa and West Africa. In South America, it started in Colombia and now affects the whole of Central and South America with the exception of Argentina, Paraguay and Peru which practically have no falciparum malaria. The mechanism of drug resistance in malaria parasites is believed to be due to gene mutation selected under drug pressure. It may be one-step as in pyrimethamine or multi-step as in chloroquine. Resistant mutation occurs both in schizogony and sporogony. The parasites lose their S strains through hybridization or overgrowth, shifting in character progressively towards high grade resistance. Policies that may help to minimise further development of resistance to existing compounds and to safeguard any new drugs that may be developed in the future include (1) limit the distribution of antimalarials; (2) select priority groups for prophylaxis; (3) use the gametocidal drug primaquine to restrict transmission of resistant strains; (4) establish an effective drug monitoring system; (5) only deploy drugs for control as part of an integrated campaign; (6) control use of new antimalarial; (7) encourage the use of tested effective drug regimens for treatment and (8) encourage research on antimalarials. © 1986.